TICKERNERD
Menu
ACADACADHealthcare · Biotechnology

ACAD Stock Forecast: ACADIA Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 2 Oct 2026
$20
+0.33% on the day

The 20 Wall Street analysts covering ACADIA Pharmaceuticals, Inc. hold a median 12-month price target of $33 — +65.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 77 of 100 as at 3 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$3.4B
Ticker Nerd rank
77 / 100
Median analyst target
$33
Analysts covering
20
Revenue$308.0M+16.4% y/y
Operating income$37.8M
Net income$31.5M
Free cash flow$95.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.5%
1M
−31.0%
YTD
−25.3%
1Y
−6.7%
From 52W high
−34.7%
From 52W low
+0.3%
$20
$31
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ACAD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ACADIA Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
77 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
98
Quality
95
Revisions
85
Volatility
82
Growth
60
Momentum
53
Issuance
38
Size
28
Accruals
19

Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (19): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ACAD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACAD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50Jan 26Apr 26Jul 26Oct 26ACADHigh $49Median $33Low $17

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says20 analysts
15 Buy4 Hold1 Sell
Low $17Median $33High $49

The green dot is the last close — the median target sits +65.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 6 moved it down.

DateFirmActionRatingTarget
25 Sept 2026BMO CapitalMaintainsOutperform$36 → $34
25 Sept 2026CitizensMaintainsMarket Outperform$36 → $33
25 Sept 2026Deutsche BankMaintainsBuy$38 → $31
25 Sept 2026HC Wainwright & Co.MaintainsBuy$37 → $33
25 Sept 2026NeedhamMaintainsBuy$41 → $35
24 Sept 2026CitigroupMaintainsBuy$40 → $33
24 Sept 2026NeedhamReiteratesBuy$41
25 Aug 2026CitigroupMaintainsBuy—
25 Aug 2026CitigroupMaintainsBuy$39 → $40
25 Aug 2026Deutsche BankMaintainsBuy—
25 Aug 2026Deutsche BankMaintainsBuy$37 → $38
25 Aug 2026Morgan StanleyMaintainsEqual-Weight$27 → $28
25 Aug 2026Morgan StanleyMaintainsEqual-Weight—
17 Aug 2026UBSMaintainsBuy—
17 Aug 2026UBSMaintainsBuy$45 → $49
12 Aug 2026NeedhamMaintainsBuy—
12 Aug 2026NeedhamMaintainsBuy$38 → $41
10 Aug 2026CitigroupMaintainsBuy—
10 Aug 2026CitigroupMaintainsBuy$35 → $39
5 Aug 2026CitizensMaintainsMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACAD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ACAD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 2 Oct 2026, ACADIA Pharmaceuticals, Inc. returned −6.7% against +16.2% for the S&P 500, dividends included.

ACAD vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140Jan 26Apr 26Jul 26Oct 26ACADS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ACAD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+56.8%
Analysts raising
13
Analysts cutting
0
Fundamentals

ACADIA Pharmaceuticals, Inc. (ACAD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
8.9×

Cheaper than 60% of US stocks

Price / sales
3.0×

Cheaper than 40% of US stocks

Price / book
2.6×

Cheaper than 36% of US stocks

EV / EBITDA
26.0×

Cheaper than 10% of US stocks

Growth & margins
Revenue growth (YoY)
16.4%

Higher than 64% of US stocks

Earnings growth (YoY)
18.1%

Higher than 56% of US stocks

Gross margin
90.8%

Higher than 96% of US stocks

Operating margin
12.3%

Higher than 68% of US stocks

Net margin
33.4%

Higher than 92% of US stocks

Returns & dividend
Return on equity
35.7%

Higher than 90% of US stocks

Return on assets
3.6%

Higher than 69% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ACADIA Pharmaceuticals, Inc. (ACAD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ACADIA Pharmaceuticals, Inc. has a market value of $3.4B and an enterprise value of $2.6B.

  • Revenue in the twelve months to 30 June 2026: $1.1B. The latest quarter grew 16.4% year on year.

  • Net income over the same four quarters: $380.5M, a 33.4% net margin.

  • Diluted earnings per share, trailing twelve months: $2.22.

  • Free cash flow in the twelve months to 30 June 2026: $145.6M.

  • Shares outstanding: 172.1M.

  • Trailing P/E: 8.9×; forward P/E: 22.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • ACADIA Pharmaceuticals, Inc. employs 796 people — $1.4M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

ACAD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ACADACADIA Pharmaceuticals, Inc.$3.4B
77
TARSTarsus Pharmaceuticals, Inc.$3.4B
82
IDYAIDEAYA Biosciences, Inc.$3.5B
78
CELCCelcuity, Inc.$3.5B
28
ELVNEnliven Therapeutics, Inc.$3.4B
65
PBLSParabilis Medicines, Inc.$3.6B
0
XENEXenon Pharmaceuticals, Inc.$3.6B
41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ACADIA Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ACAD news & analysis

Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041

Zacks Investment Research · 29 Sept 2026positive

Acadia Pharmaceuticals received a patent allowance for Daybue that could extend U.S. protection of the drug to March 2041. The company also reported strong sales growth for trofinetide and gained European approval for the drug.

Why it matters — Extended patent protection for Daybue and its expanding commercial footprint in the U.S. and Europe could strengthen the long-term outlook for ACAD's key trofinetide franchise.

Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041

Business Wire · 28 Sept 2026positive

Acadia Pharmaceuticals announced that the USPTO has issued a Notice of Allowance for its U.S. patent application covering weight-banded dosing of trofinetide for the treatment of Rett syndrome. The patent is expected to issue following completion of standard administrative procedures, extending U.S. patent protections to March 2041.

Why it matters — The allowance extends U.S. patent protection for trofinetide to March 2041, which could strengthen the company's intellectual property position for its Rett syndrome treatment.

3 Stocks Put Traders Are Targeting Today: AMTX, ACAD, REZI

Schaeffers Research · 28 Sept 2026negative

Schaeffers Research reports that options bears are circling ACAD and two other stocks today, with put volume substantially outpacing call volume. The unusually heavy put activity indicates bearish sentiment among options traders toward ACAD.

Why it matters — Heavy put activity signals that options traders are positioning bearishly on ACAD, which could indicate negative market sentiment toward the stock.

ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal

Zacks Investment Research · 25 Sept 2026negative

Acadia Pharmaceuticals' stock fell 13% after its Phase II study for Alzheimer's psychosis narrowly missed its primary goal, though the 60 mg results supported continued Phase III development.

Why it matters — The setback in the Alzheimer's psychosis program is significant for ACAD watchers given its implications for a key pipeline candidate, though the 60 mg data keeps the drug moving toward Phase III.

ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis Transcript

Seeking Alpha · 24 Sept 2026neutral

ACADIA Pharmaceuticals discussed the top-line Phase II results from its RADIANT study of remlifanserin for Alzheimer's disease psychosis, as presented in a transcript on Seeking Alpha. The discussion covers the data from this clinical trial.

Why it matters — A watcher of ACAD would care because the RADIANT Phase II results for remlifanserin represent key clinical progress for a pipeline candidate targeting Alzheimer's disease psychosis.

FAQ

Frequently asked questions about ACAD stock

What is the ACAD stock price forecast for 2026-2027?

The 20 Wall Street analysts covering ACADIA Pharmaceuticals, Inc. have a median 12-month price target of $33, with estimates ranging from $17 to $49. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ACAD stock a buy right now?

Of the 20 analysts covering ACADIA Pharmaceuticals, Inc., 15 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks ACADIA Pharmaceuticals, Inc. 77 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACAD?

As at 3 Oct 2026, ACADIA Pharmaceuticals, Inc. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).

Will ACAD stock go up?

No one can know that. What the data says: the median 12-month target from 20 analysts implies +65.4% from the last close, and Ticker Nerd's factor model ranks ACADIA Pharmaceuticals, Inc. 77 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ACAD stock forecast for 2030?

No analyst covering ACADIA Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACAD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $49 over the next 12 months.

How has ACAD stock performed over the past year?

ACADIA Pharmaceuticals, Inc. returned -6.7% over the 12 months to 2 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ACADIA Pharmaceuticals, Inc. do?

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system disorders and rare diseases.

What is the latest news on ACAD?

The most recent item we track (Zacks Investment Research, 29 Sept 2026): "Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041". Acadia Pharmaceuticals received a patent allowance for Daybue that could extend U.S. protection of the drug to March 2041. The company also reported strong sales growth for trofinetide and gained European approval for the drug.

Company

About ACADIA Pharmaceuticals, Inc.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system disorders and rare diseases. The company’s commercial portfolio includes treatments for Parkinson’s disease psychosis and Rett syndrome, reflecting its emphasis on neuropsychiatric and neuro-rare conditions with limited treatment options. Acadia Pharmaceuticals Inc. also maintains a clinical and research pipeline targeting additional unmet needs in neuroscience, including programs in Alzheimer’s disease psychosis, Lewy body dementia psychosis, and other rare or underserved patient populations. Based in San Diego, California, the company serves as a specialized player in the healthcare market, combining drug development, regulatory expertise, and commercialization capabilities to support patients, caregivers, and healthcare providers across its therapeutic areas.

CEO Ms. Catherine E. Owen Adams · 796 employees · United States · https://acadia.com